RT @N_Konduri: Clear data on a known #access2meds problem Top 20 #BigPharma innovation is *not* associated with DALYs in LMICs and LICs.…
RT @N_Konduri: Clear data on a known #access2meds problem Top 20 #BigPharma innovation is *not* associated with DALYs in LMICs and LICs.…
RT @N_Konduri: Clear data on a known #access2meds problem Top 20 #BigPharma innovation is *not* associated with DALYs in LMICs and LICs.…
RT @N_Konduri: Clear data on a known #access2meds problem Top 20 #BigPharma innovation is *not* associated with DALYs in LMICs and LICs.…
Clear data on a known #access2meds problem Top 20 #BigPharma innovation is *not* associated with DALYs in LMICs and LICs. Study was funded by Korean entities @Margo_E_Warren @damidefelice @JayasreeKIyer https://t.co/a64mqF6I7E https://t.co/RAnmIcPfpA
Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study https://t.co/2E8ziDLvLT